Texiobactin, a Potent Killer of Antibiotic Resistant Pathogens

Madeeha Arooj; Young-Sang Koh

doi:10.4167/jbv.2017.47.2.102

Journal List > J Bacteriol Virol > v.47(2) > 1034256

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Arooj and Koh: Texiobactin, a Potent Killer of Antibiotic Resistant Pathogens

Research Update (Minireview)

J Bacteriol Virol 2017;47(2):102-104.

Published online: 9 February 2017

DOI: https://doi.org/10.4167/jbv.2017.47.2.102

Texiobactin, a Potent Killer of Antibiotic Resistant Pathogens

Madeeha Arooj, Young-Sang Koh^∗

Department of Microbiology and Immunology, School of Medicine and Brain Korea 21 PLUS Program, and Jeju Research Center for Natural Medicine, Jeju National University, Jeju, Korea

^∗Corresponding author: Young-Sang Koh. Department of Microbiology and Immunology, Jeju National University School of Medicine, 102 Jejudaehakno, Jeju 63243, Korea. Phone: +82-64-754-3851, Fax: +82-64-702-2687, e-mail: yskoh7@jejunu.ac.kr

^∗∗ This research was supported by the 2017 scientific promotion program funded by Jeju National University.

Received 12 June 201714 June 2017 Accepted 14 June 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Antibiotic resistance is a major global concern that primarily affects public health. Texiobactin is a newly discovered antibiotic produces by soil microbes isolated from natural environment. Drug is active against Gram-positive bacteria as it inhibits biosynthesis of peptidoglycan. Infection of methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae in mice elicits a good response reduce bacterial load. Although extensive efforts have been made to discover new antibiotics but results are still not satisfactory to meet the demands of public health. Recently it has been shown that the discovery of texiobactin by iChip will be a great stone mile to discover more antibiotics.

Keywords: Texiobactin, Peptidoglycan, MRSA, iChip

REFERENCES

1). Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015; 517:455–9.

2). Pham VH, Kim J. Cultivation of unculturable soil bacteria. Trends Biotechnol. 2012; 30:475–84.

3). Wright G. Antibiotics: An irresistible newcormer. Nature. 2015; 517:442–4.

4). Nichols D, Cahoon N, Trakhtenberg EM, Pham L, Mehta A, Belanger A, et al. Use of Ichip for High-Throughput In Situ Cultivation of "Uncultivable" Microbial Species. Appl Environ Microbiol. 2010; 76(2445):50.

5). Willems RJ, Homan W, Top J, van Santen-Verheuvel M, Tribe D, Manzioros X, et al. Variant esp gene as a maker of a distinct genetic lineage of vancomycin-resistant Enterococcus faecium spreading in hospitals. Lancet. 2001; 357:853–5.

6). Hendrickx AP, Bonten MJ, van Luit-Asborek M, Schapendonk CM, Kragten AH, Willems RJ. Expression of two distinct types of pili by a hospital-acquired Enterococcus faecium isolate. Microbiology. 2008; 154:3212–23.

7). Hendrickx AP, van Wamel WJ, Posthuma G, Bonten MJ, Willems RJ. Five genes encoding surface-exposed LPXTG proteins are enriched in hospital-adapted Enterococcus faecium clonal complex 17 isolates. J Bacteriol. 2007; 189:8321–32.

8). Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012; 10:266–78.

9). Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, et al. Metagenomics analysis of stool microbiome in patients receiving allogenic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2014; 20:640–5.

10). Homma T, Nuxoll A, Gandt AB, Ebner P, Engels I, Schneider T, et al. Dual Targeting of Cell Wall Precursors by Teixobactin Leads to Cell Lysis. Antimicrob Agents Chemother. 2016; 60:6510–17.

11). Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011; 469:543–7.

TOOLS

Similar articles